Litcius/Paper detail

A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation

Sisi Kang, Mei Yang, Suhua He, Yueming Wang, Xiaoxue Chen, Yao-Qing Chen, Zhongsi Hong, Jing Liu, Guanmin Jiang, Qiuyue Chen, Ziliang Zhou, Zhechong Zhou, Zhaoxia Huang, Xi Huang, Huanhuan He, Weihong Zheng, Hua‐Xin Liao, Fei Xiao, Hong Shan, Shoudeng Chen

2021Nature Communications92 citationsDOIOpen Access PDF

Abstract

Although human antibodies elicited by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein are profoundly boosted upon infection, little is known about the function of N-reactive antibodies. Herein, we isolate and profile a panel of 32 N protein-specific monoclonal antibodies (mAbs) from a quick recovery coronavirus disease-19 (COVID-19) convalescent patient who has dominant antibody responses to the SARS-CoV-2 N protein rather than to the SARS-CoV-2 spike (S) protein. The complex structure of the N protein RNA binding domain with the highest binding affinity mAb (nCoV396) reveals changes in the epitopes and antigen's allosteric regulation. Functionally, a virus-free complement hyperactivation analysis demonstrates that nCoV396 specifically compromises the N protein-induced complement hyperactivation, which is a risk factor for the morbidity and mortality of COVID-19 patients, thus laying the foundation for the identification of functional anti-N protein mAbs.

Topics & Concepts

HyperactivationVirologyAntibodyEpitopeMonoclonal antibodyCoronavirusAllosteric regulationComplement systemBiologyAntigenSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Viral structural proteinCoronavirus disease 2019 (COVID-19)ImmunologyVirusViral entryMedicineDiseaseViral replicationCell biologyInfectious disease (medical specialty)ReceptorGeneticsPathologySARS-CoV-2 and COVID-19 ResearchComplement system in diseasesCOVID-19 Clinical Research Studies